Advances in targeted therapy of malignant lung tumors have been led by the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) which are widely applied in the clinic as the standard first-line option for treating EGFR-mutant NSCLC with category 1 recommendations 8. The gene discussed is EGFR; the disease is cancer.